Genflow Biosciences PLC Announces Issue of Equity
Genflow Biosciences (OTCQB:GENFF) has successfully raised £340,000 through the issuance of 40,000,000 new ordinary shares at 0.85 pence per share. The transaction involves CEO Eric Leire initially subscribing to the shares under an employee offer exemption, who will then direct their issuance to an institution for immediate sale to an identified purchaser.
The purchaser will receive one-for-one warrants exercisable for 24 months at 1.2 pence. Upon admission of the new shares expected around October 9, 2025, the company's total issued shares will increase to 493,547,942. The funding will provide essential working capital and support ongoing dog studies while awaiting the Wallonia region grant's first payment.
Genflow Biosciences (OTCQB:GENFF) ha raccolto con successo £340,000 mediante l’emissione di 40.000.000 nuove azioni ordinarie a 0,85 penny per azione. L’operazione prevede che il CEO Eric Leire sottoscriva inizialmente le azioni nell’ambito di un’esenzione offerta ai dipendenti, per poi indirizzare l’emissione a un’istituzione per una vendita immediata a un acquirente identificato.
L’acquirente riceverà warrant come 1:1 esercitabili per 24 mesi a 1,2 penny. All’ammissione delle nuove azioni prevista intorno al 9 ottobre 2025, il totale delle azioni emesse della società salirà a 493.547.942. Il finanziamento offrirà capitale circolante essenziale e sosterrà gli studi sui cani in corso in attesa del primo pagamento della sovvenzione della regione Vallonia.
Genflow Biosciences (OTCQB:GENFF) ha recaudado con éxito £340,000 mediante la emisión de 40.000.000 de nuevas acciones ordinarias a 0,85 peni por acción. La operación implica que el CEO Eric Leire suscriba inicialmente las acciones bajo una exención de oferta para empleados, y luego dirija su emisión a una institución para su venta inmediata a un comprador identificado.
El comprador recibirá warrants uno a uno, exercitables por 24 meses a 1,2 peni. Con la admisión de las nuevas acciones prevista alrededor del 9 de octubre de 2025, el total de acciones emitidas de la empresa aumentará a 493,547,942. La financiación proporcionará el capital de trabajo esencial y apoyará los estudios de perros en curso mientras se espera el primer pago de la subvención de la región de Valonia.
Genflow Biosciences (OTCQB:GENFF)가 £340,000를 성공적으로 조달했으며, 40,000,000주의 신규 보통주를 주당 0.85페니에 발행했습니다. 이번 거래에서 CEO Eric Leire가 초기에는 직원 혜택 예외에 따라 주식을 구독하고, 이후 이를 특정 기관에 발행하여 식별된 매수인에게 즉시 매각되도록 지시합니다.
매수인은 24개월 동안 1.2페니의 행사 가능한 원-포-원(warrants)을 받게 됩니다. 새로운 주식의 상장 예정일이 2025년 10월 9일경으로 예상되며, 회사의 총 발행 주식 수는 493,547,942주로 증가합니다. 이 자금은 필수 운전자본을 제공하고 벨기에 왈로나 지역 보조금의 첫 지급을 기다리는 동안 진행 중인 개 연구를 지원할 것입니다.
Genflow Biosciences (OTCQB:GENFF) a levé avec succès £340 000 grâce à l’émission de 40 000 000 de nouvelles actions ordinaires à 0,85 penny par action. L’opération prévoit que le PDG Eric Leire souscrive initialement les actions dans le cadre d’une exemption d’offre pour les employés, puis orientera leur émission vers une institution pour une vente immédiate à un acquéreur identifié.
L’acquéreur recevra des warrants 1 pour 1 exerçables pendant 24 mois à 1,2 penny. Lors de l’admission des nouvelles actions, estimée autour du 9 octobre 2025, le nombre total d’actions en circulation passera à 493 547 942. Le financement fournira le fonds de roulement essentiel et soutiendra les études sur les chiens en cours en attendant le premier paiement de la subvention de la région wallonne.
Genflow Biosciences (OTCQB:GENFF) hat erfolgreich £340.000 durch die Ausgabe von 40.000.000 neuen Stammaktien zu 0,85 Pence pro Aktie aufgenommen. Die Transaktion sieht vor, dass der CEO Eric Leire zunächst die Aktien im Rahmen einer Mitarbeiterangebot-Ausnahme zeichnen wird, bevor er deren Emission an eine Institution weiterleitet, die sie umgehend an einen identifizierten Käufer verkauft.
Der Käufer erhält One-for-One-Warrants, die 24 Monate zu 1,2 Pence ausübbar sind. Mit der voraussichtlichen Zulassung der neuen Aktien um den 9. Oktober 2025 wird die insgesamt ausgegebene Aktienanzahl der Gesellschaft auf 493.547.942 steigen. Die Finanzierung wird essentielles Working Capital bereitstellen und die laufenden Hundestudien unterstützen, während auf die erste Auszahlung des Wallonien-Zuschusses gewartet wird.
Genflow Biosciences (OTCQB:GENFF) نجحت في جمع 340,000 ليرة إسترلينية من خلال إصدار 40,000,000 سهم عادي جديد بسعر 0.85 بنس للسهم. تتضمن الصفقة اشتراك الرئيس التنفيذي إريك ليير مبدئياً في الأسهم بموجب استثناء عرض للموظفين، ثم تحويل إصدار الأسهم إلى مؤسسة لبيعها فوراً لمشتري محدد.
سيحصل المشتري على حقوق أقدمية بسهم واحد مقابل سهم واحد قابلة للتنفيذ لمدة 24 شهرًا بسعر 1.2 بنس. عند إدراج الأسهم الجديدة المتوقع حوالي 9 أكتوبر 2025، سيزيد إجمالي الأسهم المُصدرة للشركة إلى 493,547,942. سيوفر التمويل رأس مال تشغيلي أساسي ويدعم دراسات الكلاب الجارية في انتظار الدفعة الأولى من منحة منطقة والونيا.
Genflow Biosciences (OTCQB:GENFF) 已通过发行<40,000,000 股新增普通股，以每股0.85 便士成功募集了£340,000。本次交易中，CEO Eric Leire 将最初在员工优惠豁免下认购这些股份，随后将其发行指向一家机构，以便立即向已锁定的购买方出售。
购买方将获得1比1的认股权证，可在<24 个月内以<1.2 便士行使。预计新股在<2025年10月9日左右上市之时，公司总发行股数将增至493,547,942股。此次融资将提供必要的营运资金，并在等待瓦隆区拨款的首笔付款时，支持正在进行的犬类研究。
- Raised £340,000 in additional working capital
- Warrants issued at 1.2 pence represent a 41% premium to issue price
- Funding secured to continue dog studies while awaiting grant payment
- 41% dilution through issuance of 40 million new shares
- Potential future dilution from warrant exercise
- Complex share issuance structure required due to prospectus requirements
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Subscription of New Ordinary Shares, Warrant Issue, PDMR Dealings
LONDON, UK, AL / ACCESS Newswire / October 2, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), is pleased to announce that it has raised gross proceeds of
Issuance of the New Ordinary Shares
The Company is currently unable to issue and admit the New Ordinary Shares without either the publication of a prospectus approved by the Financial Conduct Authority ("FCA") or relying upon an exemption to the requirement to issue a prospectus.
Consequentially, this fundraise involves a subscription by Eric Leire, CEO and director of the Company, for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and 1(5) (h) of the UK Prospectus Regulation.
Following allotment of the New Ordinary Shares, Eric Leire has agreed to direct their issue to an institution, who will immediately sell these New Ordinary Shares at the same Issue Price to a purchaser identified by it (the "Purchaser").
Warrants
Concurrent with the purchase of the New Ordinary Shares, the Purchaser will receive warrants from the Company on a one-for-one basis. These warrants will be exercisable for a period of 24 months at an exercise price of 1.2 pence ("Exercise Price").
Total Voting Rights
Application will be made for the 40,000,000 New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 9 October 2025 (the "Admission").
Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 493,547,942.
The above figure of 493,547,942 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Dr. Eric Leire, CEO of Genflow, commented: "We appreciate the continuing support from our US backer, and this will enable us to continue with dog study whilst awaiting the first payment of the Wallonia region grant. This financing provides Genflow with essential working capital while aligning long-term interests through the concurrent issue of warrants."
UK Market Abuse Regulation (UK MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Genflow Biosciences is Eric Leire, Chief Executive Officer.
Notification of transactions of directors, persons discharging managerial responsibilities or connected persons
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||
a) | Name | Eric Leire | ||||||||
2. | Reason for the Notification | |||||||||
a) | Position/status | PDMR | ||||||||
b) | Initial notification / Amendment | Initial notification | ||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | Genflow Biosciences plc | ||||||||
b) | LEI | 213800HVOFXRXVEGDN62 | ||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of | ||||||||
Identification Code | GB00BP2C3V08 | |||||||||
b) | Nature of the transaction | Off Market Allotment | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information: Aggregated volume Price | 40,000,000 Ordinary Shares 0.85 pence per Ordinary Share | ||||||||
e) | Dates of the transaction | 2 October 2025 | ||||||||
f) | Place of the transactions | London | ||||||||
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
DISCLAIMER
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.
This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
How much capital did Genflow Biosciences (GENFF) raise in the October 2025 equity offering?
What are the terms of the warrants issued by Genflow Biosciences in October 2025?
How many shares will Genflow Biosciences have outstanding after this equity issuance?
What will Genflow Biosciences use the proceeds for?
Who purchased the new shares in Genflow's October 2025 offering?
